IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers
Gastric and colorectal cancers are leading causes of death worldwide. Although a relationship between inflammation and the innate immunity in cancer-bearing hosts is widely accepted, the precise cell mechanisms mediating this relationship have not been elucidated. The aim of this study was to invest...
Gespeichert in:
| Veröffentlicht in: | Annals of Cancer Research and Therapy 2017/08/08, Vol.25(2), pp.67-76 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 76 |
|---|---|
| container_issue | 2 |
| container_start_page | 67 |
| container_title | Annals of Cancer Research and Therapy |
| container_volume | 25 |
| creator | Minamikawa, Kazuo Shibata, Masahiko Gonda, Kenji Ujiie, Daisuke Ashizawa, Mai Nakajima, Takahiro Okayama, Hirokazu Sakamoto, Wataru Saito, Motonobu Momma, Tomoyuki Mimura, Kousaku Ohki, Shinji Shimura, Tatsuo Ohto, Hitoshi Takenoshita, Seiichi Kono, Koji |
| description | Gastric and colorectal cancers are leading causes of death worldwide. Although a relationship between inflammation and the innate immunity in cancer-bearing hosts is widely accepted, the precise cell mechanisms mediating this relationship have not been elucidated. The aim of this study was to investigate the status of systemic inflammation, immune suppression, malnutrition, and prognosis associated with interleukin (IL)-17 and vascular endothelial growth factor (VEGF) in patients with gastric and colorectal cancers.The production of IL-17 and the serum levels of VEGF in patients with gastric and colorectal cancers were up-regulated in advanced stages of the diseases, which were positively correlated with the levels of myeloid-derived suppressor cells, the neutrophil-to-lymphocyte ratio, and C-reactive protein, while both were inversely correlated with IL-12 production, stimulation index, and nutritional markers including prealbumin and retinol binding protein. Overall survival of patients with stage III and IV gastric or colorectal cancer was significantly worse for patients with high IL-17 production or high VEGF levels than for those with low IL-17 production or low VEGF levels. The observations in the present study suggest that IL-17 and VEGF are closely associated with disease progression, and may serve as useful markers of the immune suppression, malnutrition, and prognosis in patients with gastric and colorectal cancers. |
| doi_str_mv | 10.4993/acrt.25.67 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2014340931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2014340931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3547-65e20862c350ab802672c3453c2c56ccf873f137ba1425f703e570bf6c83cc383</originalsourceid><addsrcrecordid>eNo9kM9uE0EMxlcIJErhwhOMxA1pw-z83Rw4oKotlSJxAa4jx_FuJ9rMhvG0KO_RB2aiRTn58-ef_Mlumo-dXJn1Wn8BzGWl7Mr5V81V1_eytcatX1etjWldr-3b5h3zXkrjrFNXzcvDpu28gLQTv2_v7wRkEhzHFIeIkMp0EsA8Y4RCO_E3lkexi0zAJI55HjMxxzmJmJ7n6TmmUfCJCx0iVmuY4HCAsszFsSpKhZclI3DJlTrn4jzNmbDAJGokUub3zZsBJqYP_-t18-vu9ufN93bz4_7h5tumRW2Nb50lJXunaidh20vlfNXGalRoHeLQez102m-hM8oOXmqyXm4Hh71G1L2-bj4te-stf56IS9jPTznVyKBkZ7SRa91V6vNCYZ6ZMw3hmOMB8il0Mpy_Hs5fD8oG5yv8dYH3XGCkCwq5RJzogqqFv_j4CDlQ0v8AoCiOOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014340931</pqid></control><display><type>article</type><title>IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers</title><source>J-STAGE (Free - Japanese)</source><source>EZB Electronic Journals Library</source><creator>Minamikawa, Kazuo ; Shibata, Masahiko ; Gonda, Kenji ; Ujiie, Daisuke ; Ashizawa, Mai ; Nakajima, Takahiro ; Okayama, Hirokazu ; Sakamoto, Wataru ; Saito, Motonobu ; Momma, Tomoyuki ; Mimura, Kousaku ; Ohki, Shinji ; Shimura, Tatsuo ; Ohto, Hitoshi ; Takenoshita, Seiichi ; Kono, Koji</creator><creatorcontrib>Minamikawa, Kazuo ; Shibata, Masahiko ; Gonda, Kenji ; Ujiie, Daisuke ; Ashizawa, Mai ; Nakajima, Takahiro ; Okayama, Hirokazu ; Sakamoto, Wataru ; Saito, Motonobu ; Momma, Tomoyuki ; Mimura, Kousaku ; Ohki, Shinji ; Shimura, Tatsuo ; Ohto, Hitoshi ; Takenoshita, Seiichi ; Kono, Koji</creatorcontrib><description>Gastric and colorectal cancers are leading causes of death worldwide. Although a relationship between inflammation and the innate immunity in cancer-bearing hosts is widely accepted, the precise cell mechanisms mediating this relationship have not been elucidated. The aim of this study was to investigate the status of systemic inflammation, immune suppression, malnutrition, and prognosis associated with interleukin (IL)-17 and vascular endothelial growth factor (VEGF) in patients with gastric and colorectal cancers.The production of IL-17 and the serum levels of VEGF in patients with gastric and colorectal cancers were up-regulated in advanced stages of the diseases, which were positively correlated with the levels of myeloid-derived suppressor cells, the neutrophil-to-lymphocyte ratio, and C-reactive protein, while both were inversely correlated with IL-12 production, stimulation index, and nutritional markers including prealbumin and retinol binding protein. Overall survival of patients with stage III and IV gastric or colorectal cancer was significantly worse for patients with high IL-17 production or high VEGF levels than for those with low IL-17 production or low VEGF levels. The observations in the present study suggest that IL-17 and VEGF are closely associated with disease progression, and may serve as useful markers of the immune suppression, malnutrition, and prognosis in patients with gastric and colorectal cancers.</description><identifier>ISSN: 1344-6835</identifier><identifier>EISSN: 1880-5469</identifier><identifier>DOI: 10.4993/acrt.25.67</identifier><language>eng</language><publisher>Tokyo: The Japanese Society of Strategies for Cancer Research and Therapy</publisher><subject>C-reactive protein ; Colorectal cancer ; Colorectal carcinoma ; Gastric cancer ; IL-17 ; immunosuppression ; Inflammation ; Innate immunity ; Interleukin 12 ; Interleukin 17 ; Malnutrition ; Medical prognosis ; Prognosis ; Serum levels ; Suppressor cells ; Vascular endothelial growth factor ; VEGF ; Vitamin A</subject><ispartof>Annals of Cancer Research and Therapy, 2017/08/08, Vol.25(2), pp.67-76</ispartof><rights>2017 by The Japanese Society of Strategies for Cancer Research and Therapy</rights><rights>Copyright Japan Science and Technology Agency 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3547-65e20862c350ab802672c3453c2c56ccf873f137ba1425f703e570bf6c83cc383</citedby><cites>FETCH-LOGICAL-c3547-65e20862c350ab802672c3453c2c56ccf873f137ba1425f703e570bf6c83cc383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,4010,27900,27901,27902</link.rule.ids></links><search><creatorcontrib>Minamikawa, Kazuo</creatorcontrib><creatorcontrib>Shibata, Masahiko</creatorcontrib><creatorcontrib>Gonda, Kenji</creatorcontrib><creatorcontrib>Ujiie, Daisuke</creatorcontrib><creatorcontrib>Ashizawa, Mai</creatorcontrib><creatorcontrib>Nakajima, Takahiro</creatorcontrib><creatorcontrib>Okayama, Hirokazu</creatorcontrib><creatorcontrib>Sakamoto, Wataru</creatorcontrib><creatorcontrib>Saito, Motonobu</creatorcontrib><creatorcontrib>Momma, Tomoyuki</creatorcontrib><creatorcontrib>Mimura, Kousaku</creatorcontrib><creatorcontrib>Ohki, Shinji</creatorcontrib><creatorcontrib>Shimura, Tatsuo</creatorcontrib><creatorcontrib>Ohto, Hitoshi</creatorcontrib><creatorcontrib>Takenoshita, Seiichi</creatorcontrib><creatorcontrib>Kono, Koji</creatorcontrib><title>IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers</title><title>Annals of Cancer Research and Therapy</title><addtitle>Ann. Cancer Res. Therap.</addtitle><description>Gastric and colorectal cancers are leading causes of death worldwide. Although a relationship between inflammation and the innate immunity in cancer-bearing hosts is widely accepted, the precise cell mechanisms mediating this relationship have not been elucidated. The aim of this study was to investigate the status of systemic inflammation, immune suppression, malnutrition, and prognosis associated with interleukin (IL)-17 and vascular endothelial growth factor (VEGF) in patients with gastric and colorectal cancers.The production of IL-17 and the serum levels of VEGF in patients with gastric and colorectal cancers were up-regulated in advanced stages of the diseases, which were positively correlated with the levels of myeloid-derived suppressor cells, the neutrophil-to-lymphocyte ratio, and C-reactive protein, while both were inversely correlated with IL-12 production, stimulation index, and nutritional markers including prealbumin and retinol binding protein. Overall survival of patients with stage III and IV gastric or colorectal cancer was significantly worse for patients with high IL-17 production or high VEGF levels than for those with low IL-17 production or low VEGF levels. The observations in the present study suggest that IL-17 and VEGF are closely associated with disease progression, and may serve as useful markers of the immune suppression, malnutrition, and prognosis in patients with gastric and colorectal cancers.</description><subject>C-reactive protein</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Gastric cancer</subject><subject>IL-17</subject><subject>immunosuppression</subject><subject>Inflammation</subject><subject>Innate immunity</subject><subject>Interleukin 12</subject><subject>Interleukin 17</subject><subject>Malnutrition</subject><subject>Medical prognosis</subject><subject>Prognosis</subject><subject>Serum levels</subject><subject>Suppressor cells</subject><subject>Vascular endothelial growth factor</subject><subject>VEGF</subject><subject>Vitamin A</subject><issn>1344-6835</issn><issn>1880-5469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNo9kM9uE0EMxlcIJErhwhOMxA1pw-z83Rw4oKotlSJxAa4jx_FuJ9rMhvG0KO_RB2aiRTn58-ef_Mlumo-dXJn1Wn8BzGWl7Mr5V81V1_eytcatX1etjWldr-3b5h3zXkrjrFNXzcvDpu28gLQTv2_v7wRkEhzHFIeIkMp0EsA8Y4RCO_E3lkexi0zAJI55HjMxxzmJmJ7n6TmmUfCJCx0iVmuY4HCAsszFsSpKhZclI3DJlTrn4jzNmbDAJGokUub3zZsBJqYP_-t18-vu9ufN93bz4_7h5tumRW2Nb50lJXunaidh20vlfNXGalRoHeLQez102m-hM8oOXmqyXm4Hh71G1L2-bj4te-stf56IS9jPTznVyKBkZ7SRa91V6vNCYZ6ZMw3hmOMB8il0Mpy_Hs5fD8oG5yv8dYH3XGCkCwq5RJzogqqFv_j4CDlQ0v8AoCiOOw</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Minamikawa, Kazuo</creator><creator>Shibata, Masahiko</creator><creator>Gonda, Kenji</creator><creator>Ujiie, Daisuke</creator><creator>Ashizawa, Mai</creator><creator>Nakajima, Takahiro</creator><creator>Okayama, Hirokazu</creator><creator>Sakamoto, Wataru</creator><creator>Saito, Motonobu</creator><creator>Momma, Tomoyuki</creator><creator>Mimura, Kousaku</creator><creator>Ohki, Shinji</creator><creator>Shimura, Tatsuo</creator><creator>Ohto, Hitoshi</creator><creator>Takenoshita, Seiichi</creator><creator>Kono, Koji</creator><general>The Japanese Society of Strategies for Cancer Research and Therapy</general><general>Japan Science and Technology Agency</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>2017</creationdate><title>IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers</title><author>Minamikawa, Kazuo ; Shibata, Masahiko ; Gonda, Kenji ; Ujiie, Daisuke ; Ashizawa, Mai ; Nakajima, Takahiro ; Okayama, Hirokazu ; Sakamoto, Wataru ; Saito, Motonobu ; Momma, Tomoyuki ; Mimura, Kousaku ; Ohki, Shinji ; Shimura, Tatsuo ; Ohto, Hitoshi ; Takenoshita, Seiichi ; Kono, Koji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3547-65e20862c350ab802672c3453c2c56ccf873f137ba1425f703e570bf6c83cc383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>C-reactive protein</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Gastric cancer</topic><topic>IL-17</topic><topic>immunosuppression</topic><topic>Inflammation</topic><topic>Innate immunity</topic><topic>Interleukin 12</topic><topic>Interleukin 17</topic><topic>Malnutrition</topic><topic>Medical prognosis</topic><topic>Prognosis</topic><topic>Serum levels</topic><topic>Suppressor cells</topic><topic>Vascular endothelial growth factor</topic><topic>VEGF</topic><topic>Vitamin A</topic><toplevel>online_resources</toplevel><creatorcontrib>Minamikawa, Kazuo</creatorcontrib><creatorcontrib>Shibata, Masahiko</creatorcontrib><creatorcontrib>Gonda, Kenji</creatorcontrib><creatorcontrib>Ujiie, Daisuke</creatorcontrib><creatorcontrib>Ashizawa, Mai</creatorcontrib><creatorcontrib>Nakajima, Takahiro</creatorcontrib><creatorcontrib>Okayama, Hirokazu</creatorcontrib><creatorcontrib>Sakamoto, Wataru</creatorcontrib><creatorcontrib>Saito, Motonobu</creatorcontrib><creatorcontrib>Momma, Tomoyuki</creatorcontrib><creatorcontrib>Mimura, Kousaku</creatorcontrib><creatorcontrib>Ohki, Shinji</creatorcontrib><creatorcontrib>Shimura, Tatsuo</creatorcontrib><creatorcontrib>Ohto, Hitoshi</creatorcontrib><creatorcontrib>Takenoshita, Seiichi</creatorcontrib><creatorcontrib>Kono, Koji</creatorcontrib><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Annals of Cancer Research and Therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minamikawa, Kazuo</au><au>Shibata, Masahiko</au><au>Gonda, Kenji</au><au>Ujiie, Daisuke</au><au>Ashizawa, Mai</au><au>Nakajima, Takahiro</au><au>Okayama, Hirokazu</au><au>Sakamoto, Wataru</au><au>Saito, Motonobu</au><au>Momma, Tomoyuki</au><au>Mimura, Kousaku</au><au>Ohki, Shinji</au><au>Shimura, Tatsuo</au><au>Ohto, Hitoshi</au><au>Takenoshita, Seiichi</au><au>Kono, Koji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers</atitle><jtitle>Annals of Cancer Research and Therapy</jtitle><addtitle>Ann. Cancer Res. Therap.</addtitle><date>2017</date><risdate>2017</risdate><volume>25</volume><issue>2</issue><spage>67</spage><epage>76</epage><pages>67-76</pages><issn>1344-6835</issn><eissn>1880-5469</eissn><abstract>Gastric and colorectal cancers are leading causes of death worldwide. Although a relationship between inflammation and the innate immunity in cancer-bearing hosts is widely accepted, the precise cell mechanisms mediating this relationship have not been elucidated. The aim of this study was to investigate the status of systemic inflammation, immune suppression, malnutrition, and prognosis associated with interleukin (IL)-17 and vascular endothelial growth factor (VEGF) in patients with gastric and colorectal cancers.The production of IL-17 and the serum levels of VEGF in patients with gastric and colorectal cancers were up-regulated in advanced stages of the diseases, which were positively correlated with the levels of myeloid-derived suppressor cells, the neutrophil-to-lymphocyte ratio, and C-reactive protein, while both were inversely correlated with IL-12 production, stimulation index, and nutritional markers including prealbumin and retinol binding protein. Overall survival of patients with stage III and IV gastric or colorectal cancer was significantly worse for patients with high IL-17 production or high VEGF levels than for those with low IL-17 production or low VEGF levels. The observations in the present study suggest that IL-17 and VEGF are closely associated with disease progression, and may serve as useful markers of the immune suppression, malnutrition, and prognosis in patients with gastric and colorectal cancers.</abstract><cop>Tokyo</cop><pub>The Japanese Society of Strategies for Cancer Research and Therapy</pub><doi>10.4993/acrt.25.67</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1344-6835 |
| ispartof | Annals of Cancer Research and Therapy, 2017/08/08, Vol.25(2), pp.67-76 |
| issn | 1344-6835 1880-5469 |
| language | eng |
| recordid | cdi_proquest_journals_2014340931 |
| source | J-STAGE (Free - Japanese); EZB Electronic Journals Library |
| subjects | C-reactive protein Colorectal cancer Colorectal carcinoma Gastric cancer IL-17 immunosuppression Inflammation Innate immunity Interleukin 12 Interleukin 17 Malnutrition Medical prognosis Prognosis Serum levels Suppressor cells Vascular endothelial growth factor VEGF Vitamin A |
| title | IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T12%3A43%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IL-17%20and%20VEGF%20are%20significantly%20associated%20with%20disease%20progression%20involving%20systemic%20inflammation%20in%20patients%20with%20gastric%20and%20colorectal%20cancers&rft.jtitle=Annals%20of%20Cancer%20Research%20and%20Therapy&rft.au=Minamikawa,%20Kazuo&rft.date=2017&rft.volume=25&rft.issue=2&rft.spage=67&rft.epage=76&rft.pages=67-76&rft.issn=1344-6835&rft.eissn=1880-5469&rft_id=info:doi/10.4993/acrt.25.67&rft_dat=%3Cproquest_cross%3E2014340931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014340931&rft_id=info:pmid/&rfr_iscdi=true |